AVITA Medical Sees Consistent Performance and Advancements Across Portfolio, Reaffirms Full-Year Guidance
AVITA Medical, a leading provider of regenerative and advanced wound care solutions, has announced its first quarter 2026 earnings results, showcasing consistent performance and advancements across its portfolio. According to the company's Q1 2026 conference call transcript reported on May 14, 2026, AVITA Medical's revenue reached approximately $19.3 million, up 4% year-over-year and around 10% sequentially.
In his remarks, Cary Vance, President and Chief Executive Officer of AVITA Medical, emphasized that the quarter marks a significant shift towards consistency and predictability in the company's operating cadence. He noted that revenue increased approximately 10% from Q4, with product demand building momentum through the quarter and continuing into April. This improvement reflects a gradual return to utilization patterns that reflect procedural demand rather than reimbursement uncertainty.
The company also highlighted continued progress across its business and advancement across its product portfolio. Specifically, Vance pointed out that all seven Medicare Administrative Contractors have published payment rates for clinician use of RECELL, the company's proprietary autologous cell harvesting system. This development has led to a gradual return to utilization patterns that reflect procedural demand rather than reimbursement uncertainty.
As a result, AVITA Medical is seeing more frequent, smaller orders, better alignment between usage and purchasing, and improved engagement across its core accounts. These dynamics indicate a shift away from past variability towards consistency and predictability going forward.
Vance also emphasized the importance of understanding that this quarter's results build on the progress made in the previous two quarters, where the company focused on stabilizing its business and improving how it operates. This effort has paid off, as operating expenses declined year-over-year, reflecting the cost-saving actions implemented in the second quarter of 2025.
The company reaffirmed its full-year guidance of $80 million-$85 million, demonstrating confidence in its ability to execute on its priorities and drive consistent performance. As Vance noted, this is not an abstract business; it's about partnering with surgeons to help patients recover and return to their lives. AVITA Medical's mission drives the company forward, and these latest results demonstrate progress towards that goal.
Overall, AVITA Medical's Q1 2026 earnings report highlights a consistent performance and advancements across its portfolio. The company's commitment to improving how it operates and delivering value to its customers is yielding positive results, and investors can expect continued execution on its priorities going forward."
